



# The Florida Society of Thoracic & Cardiovascular Surgeons

2012 Annual  
Scientific Program  
July 13 – 15, 2012

## PATIENT BLOOD MANAGEMENT / BLOOD CONSERVATION

Aryeh Shander, MD, FCCM, FCCP

Chief, Department of Anesthesiology, Critical Care and Hyperbaric Medicine.  
Englewood Hospital and Medical Center, Englewood, New Jersey

Clinical Professor of Anesthesiology, Medicine and Surgery  
Mount Sinai School of Medicine, New York



The Institute for  
Patient Blood Management &  
Bloodless Medicine and Surgery



ENGLEWOOD  
HOSPITAL AND MEDICAL CENTER  
AN AFFILIATE OF MOUNT SINAI SCHOOL OF MEDICINE

# Disclosure


Speakers bureau: Baxter, Zymogenetics, Novartis, CSL, Coviden and Masimo

Grants: Centocor OBI, Zymogenetics, Novartis and Masimo

Consultant: Baxter, Centocor OBI, Novartis, J&J, CSL, AMAG and Vifor



# Blood: An Emotional Topic



“...the sweeping story of a substance that has been feared, revered, mythologized, and used in magic and medicine from earliest times — a substance that has become the center of a huge, secretive, and often dangerous worldwide commerce.”

—From the publisher’s description of the book

Starr D. *Blood: An Epic History of Medicine and Commerce*.  
New York, NY: HarperCollins Publishers; 2000.

# Introduction & objectives


- ◆ Issues with blood
- ◆ Anemia
- ◆ Transfusion
- ◆ Patient outcome
- ◆ What to do about it

# BLOOD TRANSFUSION

- ◆ USDHSS: In 2006, total of 14,650,000 units of RBC/WB transfused in the U.S.
  - ◆ 3.3% increase from 2004
  - ◆ ~ 20% in cardiac surgery
- ◆ AHRQ: in 2007, blood transfusions occurred in 1/10 of all hospital stays that had a procedure
  - ◆ A cumulative growth of 140% from 1997
  - ◆ One of the fastest growing top-five procedures



# Inventory pressure



1. van derPoel, C.L. and M.P. Janssen, *Final Report - The collection, testing and use of blood and blood products in Europe in 2002*. 2005: Strasbourg.
2. van derPoel, C.L. and M.P. Janssen, *Final Report - The collection, testing and use of blood and blood products in Europe in 2003*. 2005: Strasbourg.
3. \*Rouger P., *Blood Transfusion in Europe: The White Book 2005*, European Network of Transfusion Medicine Societies

# SUPPLY - BLOOD CENTERS

American Red Cross (ARC) <sup>1,2</sup>	American Blood Centers (ABC) <sup>3,4</sup>	Blood Systems <sup>5</sup>
<ul style="list-style-type: none"> <li>• Responsible for ~45% of US blood supply</li> <li>• Largest single supplier of US blood supply</li> <li>• Leader in research and testing</li> <li>• Implemented the first nationwide hemo- vigilance program</li> <li>• Protocol development and safer transfusions</li> </ul>	<ul style="list-style-type: none"> <li>• Conglomerate of smaller blood centers in US and Canada</li> <li>• 685 donor centers in 45 states</li> <li>• Responsible for ~55% of US blood supply</li> <li>• Members represent 77 community-based blood donor centers</li> <li>• Provide blood products to more than 3500 health care facilities and hospitals</li> </ul>	<ul style="list-style-type: none"> <li>• Represent ~9% of ABC's US share of blood supply<sup>3</sup></li> <li>• Testing divided into laboratories in Arizona and Texas</li> <li>• Developed UBS               <ul style="list-style-type: none"> <li>— Centralized donor testing operation</li> <li>— Review and approve SOPs</li> <li>— Validate blood product protocol</li> <li>— Record quality control records</li> </ul> </li> </ul>

SOP, standard operating procedure; UBS, United Blood Service.

1. ARC. 50 Quick Facts. [www.givelife2.org/sponsor/quickfacts.asp](http://www.givelife2.org/sponsor/quickfacts.asp). 2. ARC. Biomedical Services. [www.redcross.org/www-files/Documents/pdf/Biomed/Bioed.pdf](http://www.redcross.org/www-files/Documents/pdf/Biomed/Bioed.pdf). 3. ABC. Our Members. <http://www.americasblood.org/go.cfm?do=BCSearch.ShowAll>. 4. ABC. It's About Life. [www.americasblood.org/go.cfm?do=Page.View&pid=29](http://www.americasblood.org/go.cfm?do=Page.View&pid=29). 5. Blood Systems. UBS. <http://www.bloodsystems.org>.

# BLOOD DEMAND (Impact of the Ageing Population)

584 TRANSFUSION Volume 50, March 2010

## BLOOD DONORS AND BLOOD COLLECTION

ALI ET AL.





Fig. 2. RBC usage per capita by age in Finland 2002 to 2006. Current annual RBC usage in Finland is 50 units per 1000 inhabitants.



# Predicted RBC Collections and Transfusions



# A CLINICIAN'S PERCEPTIONS

- Safety of BLOOD - **high**
  - Risk of BLOOD - **low**
- Risk of Anemia - **unknown**
- Risk of Surgical Bleeding – **low**
  - Transfusions- **rare**



# TRANSFUSION of Allogeneic Blood

- ◆ Past: Considered a therapeutic intervention
- ◆ Present/future: A negative outcome

WHY?

# TRANSFUSION of Allogeneic Blood

- ◆ Transfusion outcome
- ◆ Transfusion risks
- ◆ Transfusion variability
- ◆ Modifiable risk (for transfusion) ignored
- ◆ We cannot continue on this journey

# Risks and Benefit “Equation”


- ◆ Variability in transfusion of ALL components
- ◆ Immediate risks – FDA and blood providers obsession – ZERO R I S K
- ◆ Unknown benefit – close to 120 years in the dark

# Efficacy Of Red Blood Cell Transfusion In The Critically Ill: A Systemic Review Of the Literature

- N = 45 articles reviewed
- Outcome measures: Mortality, Infections, MODS, ARDS
- 42 of the 45 studies showed the risks of RBC transfusion outweighed the benefits
- In adult, ICU, trauma, and surgical patients, RBC transfusions are associated with increased morbidity and mortality


# Efficacy Of Red Blood Cell Transfusion In The Critically Ill: A Systemic Review Of the Literature

Association between blood transfusion and the **risk of death** (odds ratio [OR] and 95% confidence interval [CI]). ACS, abdominal compartment syndrome; ICU, intensive care unit



# Efficacy Of Red Blood Cell Transfusion In The Critically Ill: A Systemic Review Of the Literature


Association between blood transfusion and the **risk of infectious** complications (odds ratio [OR] and 95% confidence interval [CI]).  
*ICU, intensive care unit*






# Efficacy Of Red Blood Cell Transfusion In The Critically Ill: A Systemic Review Of the Literature

Association between blood transfusion and the risk of developing **adult respiratory distress** syndrome (odds ratio [OR] and 95% confidence interval [CI]). ICU, intensive care unit



# Blood Transfusion: Who is at risk



# Side Effects And Hazards For RBC Transfusion

- Acute and delayed hemolytic transfusion reactions
- Transfusion-related acute lung injury (TRALI)
- Administrative errors
- Bacterial contamination
- Storage lesions
- Viral transmission (eg, CMV, HIV, HBV, HCV)
- **Alloimmunization**
- Volume overload
- **Iron overload**

# The Coming Plague?

“It is sobering to consider that if a new agent with a long silent carrier state and efficient blood transmission (HIV prototype) were to appear, the blood component collectors would be scarcely better prepared to interdict a transfusion transmitted epidemic than they were during the early days of AIDS in 1977.”

*Klein H. Emerging Infectious Disease and Blood Transfusion TATM 2005;7(1):18*



**U.S. Department of  
Health and Human  
Services**



**National Institutes  
of Health**

# Transfusion Medicine In American Undergraduate Medical Education

- ◆ Transfusion is the most common procedure in hospitals
- ◆ N = 86 American medical schools surveyed (AAMC)
- ◆ 83% administrators reported - didactic lectures
- ◆ 48% of medical schools providing 1 or 2 hours of lectures  
Handful reported small group sessions on transfusion medicine (6%)
- ◆ 92% administrators were unfamiliar with the 1989 or the 1995 TMAA curricula.

# Transfusion Practice


## *Influence of knowledge and attitudes on the quality of physicians' transfusion practice*

- Amount of transfused products was inversely proportional to physician knowledge of transfusion medicine
- Attending MD - lower scores, greater confidence than residents
- >60% of residents inappropriate transfusion due attending pressure (once a month)

# Variability of Transfusion Rates For Matched Patients

*Gombotz H, Rehak P, Shander A, Hofmann A..  
Transfusion 2007*

TKR – Txn Rate (n=1,401)




# Variation In Use Of Blood Transfusion In CABG Surgery

- ◆ To assess variation in use of allogeneic red blood cell (RBC), FFP, and platelet transfusions in patients undergoing (CABG) surgery.
- ◆ N = 102 470 CABG patients in 2008 at 798 sites in the US (STS Adult Cardiac Surgery Database)
- ◆ The rates of transfusions ranged from:
  - ◆ 7.8% to 92.8% for RBCs
  - ◆ 0% to 97.5% for fresh-frozen plasma
  - ◆ 0.4% to 90.4% for platelets.
- ◆ Multivariable analysis transfusion rates varied by:
  - ◆ *Geographic location (P=.007), Academic status (P=.03), and Hospital volume (P<.001)*
- ◆ Wide variability in rates of transfusion of all blood products in CABG operations in US hospitals




# Variation in use of blood transfusion in CABG surgery

Bennett-Guerrero E *et al.* JAMA 2010




# WHO Definition of Anemia and Hgb. Distribution in General population



# Anemia Is Often “Accepted” As A Normal Part Of Doing Business

- ◆ We have a long tradition of accepting anemia as a relatively harmless problem that can be **corrected easily with transfusion**
- ◆ For the medical community transfusion as treatment for anemia remains a **default position**
- ◆ New paradigm - Anemia is an independent risk of morbidity and mortality regardless of the level of hemoglobin

# Anemia: A Potent Multiplier of Mortality



N = 1.1 million (5% Medicare sample, 1996-1997)


Herzog CA, Muster HA, Li S, Collins AJ. Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population. *J Card Fail* 2004; 10:467-472.

# ANEMIA IN THE ELDERLY


Pang WW et.al

- UAE
- IDA
- AI
- AI & CKD
- CKD
- Folate and/or B12 deficiency
- Hem Malign
- Thal
- Susp MDS
- Other
- Incomplete
- Therapy for non-Hem Malign


**NHANES III**



**Chicago**




**SHC/VAPAHCS**



# Diagnostic Blood Loss From Phlebotomy and Hospital-Acquired Anemia (HAA) During Acute Myocardial Infarction

- ◆ N= 17 676 patients with AMI from 57 US hospitals - AMI database ( Jan 2000- Dec 2008)
- ◆ Moderate to severe HAA developed in 3551 patients (20%).
- ◆ The mean (SD) phlebotomy volume was higher :
  - HAA (173.8 [139.3] mL) vs those without HAA (83.5 [52.0 mL];  $P < .001$ )
- ◆ There was significant variation in the mean diagnostic blood loss across hospitals
  - For every 50 mL of blood drawn, the risk of moderate to severe HAA increased by 18% (relative risk [RR], 1.18; 95% confidence interval [CI], 1.13-1.22)
- ◆ Blood loss from phlebotomy is **independently associated** with the development of HAA.

# Variation in mean diagnostic blood loss (DBL) across the 57 hospitals



# Does Preoperative Anemia Adversely Affect Colon and Rectal Surgery Outcomes?

- 2005-2008 - NSQIP (251 hospitals)
- CO – MI, CVA, AKI, Mortality and HLOS
- N – 23,348 – 47.4 % Anemic
- Uni, multi, logistic regression and propensity scoring


Anemia	HCT	N	CO - OR	HLOS
None	(>38%)	12,281	1.0	-
Mild	(30-37%)	9037	1.47	-
Moderate	(26-29%)	1726	1.87	1.2
Severe	(21-25%)	304	2.1	1.6



# Preoperative Anemia Is Associated With Postoperative Mortality

N – 7759 2003 – 2006

Hb < 12 g/dL for women and < 13 g/dL for men



# Association between Intra-operative Blood Transfusion and Mortality and Morbidity in Patients Undergoing Non-Cardiac Surgery

- ◆ N= 10,100 patients (general, vascular, or orthopedic surgery)
- ◆ Intraoperative blood transfusion associated with an increased risk of death (odds ratio [OR], 1.29; 95% CI, 1.03–1.62)
- ◆ Patients receiving one or two units of erythrocytes more likely to have:
  - ◆ Pulmonary complications (OR, 1.76; 95% CI, 1.48–2.09)
  - ◆ Sepsis (OR, 1.43; 95% CI, 1.21–1.68)
  - ◆ Thromboembolic complications (OR, 1.77; 95% CI, 1.32–2.38)
  - ◆ Wound complications (OR, 1.87; 95% CI, 1.47–2.37)
- ◆ Intraoperative blood transfusion is associated with a **higher risk** of mortality and morbidity in surgical patients with severe anemia

# Impact of Intraoperative Transfusion on 30-Day Mortality and 30-Day Complications

Outcome	Transfusion Group, Outcome Rate %	No Transfusion Group, Outcome Rate (%)	Adj OR Txf vs. No Txf (95% CI)
Mortality	6.44	4.26	1.29 (1.03, 1.62)
Cardiac complications	2.08	1.40	1.40 (0.97, 2.03)
Pulmonary complications	12.6	6.03	1.76 (1.48, 2.09)
Renal complications	2.69	1.85	1.32 (0.93, 1.88)
CNS complications	0.69	0.58	0.84 (0.43, 1.64)
Sepsis complications	16.4	9.81	1.43 (1.21, 1.68)
Wound complications	9.17	4.65	1.87 (1.47, 2.37)
Thrombo-embolic Complications	4.07	1.89	1.77 (1.32, 2.38)

## Risk ratios (95% CI) compared with patients receiving no blood products by timing of administration

Outcome	Intra operative	Within 48 h postop	After 48 h postop
<b>In-hospital mortality</b>	7.71 (4.44–13.38)	7.09 (3.95–12.72)	10.37 (5.21–20.63)
<b>Acute renal failure</b>	3.98 (2.77–5.74)	4.12 (2.82–6.03)	10.78 (7.03–16.52)
<b>Sepsis/ DSWI</b>	3.74 (1.85–7.57)	4.11 (1.99–8.48)	11.84 (5.56–25.23)


# Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery

## FOCUS Trial

- ◆ 2016 subjects from 42 Hosp 60% US
  - ◆ Patients with Hip Fx > 50 y/o ~ 82 y/o
  - ◆ Randomized to Hb 10 (L) or 8(R) with symptoms
  - ◆ 1° - Death or walk across the room in 60 days
  - ◆ # 1 reason for Tx in R – Tachycardia and Hypotension
  - ◆ Results show no difference in outcome
1. Liberal group received 65% more transfusion

# Outcomes in Patients with Acute Myocardial Infarction

Aronson D, Dann EJ, Bonstein L, Blich M, Kapeliovich M, Beyar R, Markiewicz W, Hammerman H.



Prospective  
database  
N=2,358  
with AMI  
8.1% of  
patients  
rcvd  
transfusion

Kaplan- Meier plots showing the crude cumulative incidence of 6-,month mortality among patients who did and those who did not receive RBC transfusion

Am J Cardiol. 2008 Jul 15;102(2):115-9. Epub 2008 May 9

# Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes

Sunil V. Rao<sup>1\*</sup>, John A. Eikelboom<sup>2</sup>, Christopher B. Granger<sup>1</sup>, Robert A. Harrington<sup>1</sup>, Robert M. Califf<sup>3</sup>, and Jean-Pierre Bassand<sup>4</sup>

European Heart Journal (2007) 28, 1193–1204



# Impact of Blood Transfusion on Short- and Long-Term Mortality in Patients With ST-Segment Elevation Myocardial Infarction

Mehdi H. Shishehbor, Surabhi Madhwal, Vivek Rajagopal, Amy Hsu, Peter Kelly, Hitinder S. Gurm, Samir R. Kapadia, Michael S. Lauer, and Eric J. Topol

*J. Am. Coll. Cardiol. Interv. 2009;2;46-53*





# There Will Be Blood

Brendan Doyle


*J. Am. Coll. Cardiol. Interv. 2009;2;54-55*

For asymptomatic patients, it would seem prudent to avoid the use of arbitrary cutoffs (such as a hemoglobin  $\geq 8$  g/dl) to trigger transfusion. With minimal potential gain to offset any adverse effects, transfusion could in theory be more likely to cause harm in these circumstances.

# ICCTO – International Consensus Conference on Transfusion Outcomes

- > 30,000 citations – 494 analysed – 450 clinical scenarios
- Appropriateness of ABT based on improving health outcomes

ALL transfused patient had Hb <7.9 g/dL  
No one appropriate if Hb  $\geq$ 8.0 g/dL




# WHY IT MATTERS?

## Mean Hospital Amount (\$) Paid per Selected Component Unit in 2006 - 2008

Component	Average Amount Paid (\$)		
	2008	2006	% Change (2006-2008)
Red cells, leukocyte filtered	223.09*	211.50	5.5*
Fresh Frozen Plasma	57.78	—	—
Plasma Frozen Within 24 Hours After Phlebotomy	53.85*	52.63	2.3*
Whole-blood-derived platelets, not leukocyte reduced or irradiated	64.98	65.54	-0.9
Apheresis platelets, leukocyte reduced	538.56*	525.05	2.6*
Cryoprecipitate	65.10*	46.67	39.5*

\*Significantly different from 2006 data.


# Activity Based Cost of Transfusion




# Outcome of Patients Who Refuse Transfusion After Cardiac Surgery

- ◆ N= 322 Witnesses and 87 453 non-Witnesses cardiac surgery patients
- ◆ Non-Witnesses, 38 467 did not receive blood transfusions and 48 986 did
- ◆ Witnesses had fewer acute complications and shorter length of stay than matched transfused patients:
  - ◆ myocardial infarction, 0.31% vs 2.8% (P = .01);
  - ◆ hospital length of stay (15th, 50th, and 85th percentiles), 5, 7, and 11 vs 6, 8, and 16 days (P <.001)
  - ◆ Witnesses had better 1-year survival (95%; 95% CI, 93%-96%; vs 89%; 95% CI, 87%-90%; P = .007)
  - ◆ Similar 20-year survival (34%; 95% CI, 31%-38%; vs 32% 95% CI, 28%-35%; P = .90)
- ◆ Blood management strategies do not appear to place patients at heightened risk for reduced long-term survival

# Mirrored histogram of propensity scores



# Survival of matched patients. Error bars indicate Kaplan-Meier estimates at 5, 10, 15, and 20 years after surgery



No. at risk	0	5	10	15	20
Jehovah's Witnesses	322	219	138	71	26
Patients who received transfusions	322	207	123	58	24

# Is fresh frozen plasma clinically effective?

## An update of a systematic review of randomised controlled trials

- Primary outcome - effect of FFP on survival
- Trials reviewed up to July 2011 (n = 21)
- Trials identified from searches of:
  - MEDLINE, EMBASE, CINAHL, *The Cochrane Library*, and the *UKBTS/SRI Transfusion Evidence Library*
- Prophylactic and therapeutic FFP use in:
  - liver disease, cardiac surgery, warfarin anticoagulation reversal, TTP treatment, plasmapheresis
- **Results: no significant benefit for FFP use across all the clinical conditions**



# “New” strategies for the optimal use of platelet transfusions

- ◆ Severe thrombocytopenia is presumed to be high risk for bleeding
- ◆ Controversy as to the optimal use of platelets (amount and timing)
- ◆ Lack of data on different regimens and clinical outcomes
- ◆ Platelet Tx strategy - needs to be addressed in clinical trials: examples of such trials:
  - ◆ *The PLADO study (Prophylactic PLAtelet Dose)*
  - ◆ *The SToP study (Strategies for the Transfusion of Platelets)*


# Established Transfusion Risks/Complications – immediate (FDA)

- Acute and delayed hemolytic transfusion reactions
- Transfusion-related acute lung injury (TRALI)
- Administrative errors
- Bacterial contamination
- Storage lesions
- Viral transmission (eg, CMV, HIV, HBV, HCV)
- Alloimmunization
- Volume overload
- Iron overload


American Association of Blood Banks, America's Blood Centers, and American Red Cross. Available at:

<http://www.aabb.org/resources/bct/Documents/coi809r.pdf>. Accessed July 2010


# Morphology of RBCs in Stored Blood



**1 Day**




**21 Days**




**35 Days**

**Time in Storage**

**Hb 3.5**




**1 Unit RBC**



# PERFUSION


## Microvascular Dysfunction as a Cause of Organ Dysfunction



FCD


# HEMORRHAGIC SHOCK

Functional capillary density predicts survivors vs. non-survivors



# Survival of donor WBC in severe trauma patients

## Quantitative allele-specific PCR






# BLOOD TRANSFUSIONS AND THE SUBSEQUENT RISKS – of Hematologic malignancies (HM)

Chang et al. *Transfusion* 2010; 50: 2249-2257

US Case-control study conducted by NCI

- 77,488 elderly HM cases and 154,509 controls
- History of transfusion in 7.9% of HM cases vs. 5.9% of controls




Patterns of elevated risk for lymphoplasmacytic and marginal zone lymphomas suggest an etiologic role for transfusion

LPL – Lymphoplasmacytic lymphoma

MZL – Marginal zone lymphoma

# Nosocomial Infections in the ICU

Taylor RW et.al. Crit Care Med 2006;34(9):2302-8



# Current Solutions

- ◆ Guidelines – *Hessel EA II. et al. (Anesth Analg. Dec 2010): Guidelines for perioperative blood transfusion and conservation in cardiac surgery: lessons and challenges*
- ◆ Education
- ◆ Blood Management
- ◆ Patient Blood Management – SABM – we have results (see NHA)
- ◆ Regulation
- ◆ Payment



# Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB

- ◆ Guideline to provide recommendations about Hgb concentration thresholds and other clinical variables that “trigger” RBC transfusions
- ◆ Systematic review of the literature only RCT (1950 – Feb, 2011 )
- ◆ Examine proportion of patients who received any RBC transfusion and the number of RBC units transfused to describe the effect of restrictive transfusion strategies on RBC use
- ◆ To determine the clinical consequences of restrictive transfusion strategies, we examined :
  - ◆ overall mortality, nonfatal myocardial infarction, cardiac events, pulmonary edema, stroke, thromboembolism, renal failure, infection, hemorrhage, mental confusion, functional recovery, and length of hospital stay

# Recommendations

- ◆ **Recommendation 1:** adhering to a restrictive transfusion strategy (7 to 8 g/dL) in hospitalized, stable patients
  - ◆ (Grade: **strong recommendation; high-quality evidence**)
- ◆ **Recommendation 2:** adhering to a restrictive strategy in hospitalized patients with preexisting cardiovascular disease and considering transfusion for patients with symptoms or a hemoglobin level of 8 g/dL or less
  - ◆ (Grade: **weak recommendation; moderate-quality evidence**)
- ◆ **Recommendation 3:** cannot recommend for or against a liberal or restrictive transfusion threshold for hospitalized, hemodynamically stable patients with the acute coronary syndrome
  - ◆ (Grade: **uncertain recommendation; very low-quality evidence**)
- ◆ **Recommendation 4:** suggests that transfusion decisions be **influenced by symptoms** as well as hemoglobin concentration
  - ◆ (Grade: **weak recommendation; low-quality evidence**).

# Effect of the perioperative blood transfusion and blood conservation in cardiac surgery clinical practice guidelines of the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists upon clinical practices

- ◆ 1402 surveys from 1061 institutions - United States (677 institutions) and Canada (34 institutions) [32% response rate]
- ◆ 78% of anesthesiologists and 67% of perfusionists reporting having read all, part, or a summary of the Guidelines.
- ◆ 26% of respondents reported 1 or more practice changes in response to the Guidelines
- ◆ Only 4 of 38 Guideline recommendations were reported by >5% of respondents to have been changed in response to the Guidelines
- ◆ Little change in clinical practices was attributed to the STS/ SCA Guidelines

Blood  
Management

```
graph TD; BM[Blood Management] --> PBM[Patient Blood Management]; BM --> DBM[Donor Blood Management]; DBM --> T[Transfusion];
```

The diagram is a flowchart on a blue background. At the top center is a yellow box labeled 'Blood Management'. Two white arrows originate from the bottom of this box: one points down and left to a yellow box labeled 'Patient Blood Management', and the other points down and right to a yellow box labeled 'Donor Blood Management'. From the bottom of the 'Donor Blood Management' box, a white arrow points down to a yellow box labeled 'Transfusion'.

Donor  
Blood  
Management

Patient  
Blood  
Management

Transfusion

# Patient blood management

*“Is the timely application of evidence based medical and surgical concepts designed to manage anaemia, optimise haemostasis, and minimise blood loss and blood transfusion in order to improve patient outcomes.”*

A multimodality approach



# SABM – Administrative And Clinical Standards For Patient Blood Management Programs

Administrative  
and Clinical Standards  
**for Patient Blood  
Management Programs**



**SOCIETY FOR THE ADVANCEMENT  
OF BLOOD MANAGEMENT®**

[www.SABM.org](http://www.SABM.org)

© 2015 Society for the Advancement of Blood Management, Inc.  
All rights reserved.

# Principles of Patient Blood Management

- ◆ 94% of transfusions in surgical patients can be attributed to:
  - ◆ low preoperative hemoglobin levels, excessive surgical blood loss, and/or inappropriate transfusion practices
- ◆ PBM relies on 3 pillars:
  - ◆ (1) optimizing hematopoiesis
  - ◆ (2) minimizing bleeding and blood loss
  - ◆ (3) harnessing and optimizing physiological tolerance of anemia


# The impact of blood conservation on outcomes in cardiac surgery: is it safe and effective?

PBM strategies used:

- ◆ Pre-op hemoglobin optimization Prin 2
- ◆ Intra-op ANH Prin 3
- ◆ Autologous transfusion (cell salvage) Prin 3
- ◆ Meticulous surgical technique Prin 3
- ◆ Endovascular vein harvesting Prin 3
- ◆ Point-of-care coagulation testing Prin 3
- ◆ Targeted pharmacotherapy Prin 3
- ◆ Tolerance of peri-operative anemia (60–70 g/L depending on patient-specific physiology) Prin 2


# Algorithm For The Detection, Evaluation, And Management Of Preoperative Anemia

Goodnough LT, Shander Aryeh. Patient Blood Management. Anesthesiology. 2012 Jun;116(6):1367-76.



# CABG outcomes PBMP vs non-PBMP

N=586





World Health Organization

Executive Board : 126<sup>th</sup> Session:  
Provisional Agenda Item 4.16  
EB 126/19 Add.1  
26<sup>th</sup> November 2009

Bearing in mind that patient blood management means that before surgery every reasonable measure should be taken **to Optimize the patient's own blood volume, to minimize the patient's Blood loss and to harness and optimize the patient-specific physiological Tolerance of anemia** following the WHO's guide for optimal clinical **use (three pillars of Patient Blood Management)**



### **DHHS Selected Recommendation on PBM:**

- Wide variability in transfusion indicated both excessive and inappropriate use of blood transfusion in the U.S.
- PBM programs have shown a significant reduction in blood use without an increase in patient harm

# TJC - National Patient Safety Goal (NPSG) overuse of treatments, procedures and tests for the hospital

- Consequences of overuse: tests, treatments and procedures
- Overuse may be defined as:  
*“The use of a health service in circumstances where the likelihood of benefit is negligible and, therefore, the patient faces only the risk of harm.”*
- The focus is to identify and eliminate overuse
- NPSG provides for incremental **implementation** and an **evaluation of the effectiveness**

# SUMMARY

- ◆ Transfusion not a science
- ◆ No demonstration of benefit = all risk!
- ◆ Directed therapy – RBC, FFP, Platelets and fluid
- ◆ Guidelines – From Hgb. alone to symptoms
- ◆ Reduce or eliminate “overuse”
- ◆ Emerging data support that:
- ◆ **PBM is safe and effective in providing better care and improving patients’ outcomes while reducing transfusion of allogeneic blood components**



Despite the cost of living,  
EVEN WHEN APPROPRIATE,  
it is still very popular,  
TRANSFUSION IS PREVENTABLE

THANK  
YOU

2012 ANNUAL MEETING  
Society for the Advancement  
of Blood Management  
**September 20-22, 2012**  
SOLDIERS AND SAILORS HALL • PITTSBURGH, PA

